Second generation direct antivirals and the way to interferon-free regimens in chronic HCV

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 4, 2012, Pages 471-485

  Lewis, Heather ^a   Cunningham, Morven ^a   Foster, Graham ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cyclophilin inhibitor; Direct acting antiviral agents; Hepatitis C virus; Non nucleotide inhibitors; NS3 4A protease inhibitor; NS5A; NS5B; Nucleotide inhibitors

Indexed keywords

ABT 333; ABT 450; ALISPORIVIR; ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DANOPREVIR; FALDAPREVIR; FILIBUVIR; IDX 184; MERICITABINE; MK 5172; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VANIPREVIR; VIRUS PROTEIN;

DRUG TARGETING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; VIRUS REPLICATION;

EID: 84870419233     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.09.008     Document Type: Article

References (82)

1. V. Lohmann, F. Korner, and J. Koch Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 285 5424 1999 Jul 2 110 113
2. T. Wakita, T. Pietschmann, and T. Kato Production of infectious hepatitis C virus in tissue culture from a cloned viral genome Nat Med 11 7 2005 Jul 791 796
3. K.D. Raney, S.D. Sharma, and I.M. Moustafa Hepatitis C virus non-structural protein 3 [HCV NS3]: a multifunctional antiviral target J Biol Chem 285 30 2010 Jul 23 22725 22731
4. K. Morikawa, C.M. Lange, and J. Gouttenoire Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus J Viral Hepat 18 5 2011 May 305 315
5. B.R. Bacon, S.C. Gordon, and E. Lawitz Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 13 2011 Mar 31 1207 1217
6. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 25 2011 Jun 23 2405 2416
7. F. Poordad, J. McCone Jr., and B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 13 2011 Mar 31 1195 1206
8. S. Zeuzem, P. Andreone, and S. Pol Telaprevir for retreatment of HCV infection N Engl J Med 364 25 2011 Jun 23 2417 2428
9. G.R. Foster, C. Hezode, and J.P. Bronowicki Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections Gastroenterology 141 3 2011 Sep 881 889 e1
10. Y. Benhamou, J. Moussalli, and V. Ratziu Results of a proof of concept study [C210] of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 4 HCV patients J Hepatol 50 Suppl. 1 2009 S6
11. C. Sarrazin, T.L. Kieffer, and D. Bartels Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 5 2007 May 1767 1777
12. T.L. Kieffer, C. Sarrazin, and J.S. Miller Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients Hepatology 46 3 2007 Sep 631 639
13. D.J. Bartels, Y. Zhou, and E.Z. Zhang Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects J Infect Dis 198 6 2008 Sep 15 800 807
14. T. Kuntzen, J. Timm, and A. Berical Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients Hepatology 48 6 2008 Dec 1769 1778
15. C. Hezode, N. Forestier, and G. Dusheiko Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 18 2009 Apr 30 1839 1850
16. J.G. McHutchison, G.T. Everson, and S.C. Gordon Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 18 2009 Apr 30 1827 1838
17. J.C. Sullivan, S. De Meyer, and D.J. Bartels Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials J Hepatol 54 S1 2011 S4
18. J.M. Pawlotsky Treatment failure and resistance with direct acting antiviral drugs against hepatitis C virus Hepatology 2011 Mar 3
19. C. Lange, and C. Sarrazin Hepatitis C: new drugs 2012 Flying Publisher Available from: http://www.flyingpublisher.com/9002.php
20. M. Fried, M. Buti, and G.J. Dore TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR phase IIb study Hepatology 54 Suppl. 1 2011 1429A
21. S. Zeuzem, T. Berg, and E. Gane TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ribavirin treatment: final SVR24 results of the ASPIRE trial J Hepatol 56 Suppl. 2 2012 S1 S2
22. N. Terrault, C. Cooper, and L.A. Balar High sustained virologic response [SVR24] rates with response-guided danoprevir [DNV; RG7227] plus pegIFN α-2a [40KD] and ribavirin [P/R] in treatment-naive HCV genotype 1 [G1] patients: results from the ATLAS study Hepatology 54 Suppl. 1 2011 398A
23. G. Everson, C. Cooper, and C. Hézode Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir-boosted danoprevir/peg-IFNα-2A/RBV in HCV genotype 1 or 4 patients: DAUPHINE week 12 interim analysis J Hepatol 56 Suppl. 2 2012 S466
24. D. Dieterich, T. Asselah, and D. Guyader SILEN C-3: treatment for 12 or 24 weeks with BI201335 combined with peginterferon alfa 2a and ribavirin [P/R] in treatment naive patients with chronic genotype 1 HCV infection J Hepatol 54 Suppl 1 2011 S27
25. M. Sulkowski, T. Asselah, and P. Ferenci Treatment with the second generation HCV protease inhibitor BI201335 results in high and consistent SVR rates - results from SILEN-C1 in treatment-naive patients across different baseline factors Hepatology 54 Suppl 1 2011 S27
26. E. Lawitz, M. Rodriguez-Torres, and A. Stoehr A phase 2B study of MK-7009 [vaniprevir] in patients with genotype 1 infection who have failed previous pegylated interferon and ribavirin treatment Hepatology 54 Suppl. 1 2011 1424A
27. E. Lawitz, F. Poordad, and E. DeJesus ABT-450/ritonavir [ABT-450/r] combined with pegylated interferon alpha-2a/ribavirin [P/R] after 3-day monotherapy in HCV genotype 1 [GT1]-Infected treatment-naïve subjects: 12-week sustained virologic response [SVR12] and safety results J Hepatol 56 Suppl. 2 2012 S470
28. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2 2010 Feb 447 462
29. M.F. McCown, S. Rajyaguru, and S. Le Pogam The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to non nucleoside polymerase or protease inhibitors Antimicrob Agents Chemother 52 5 2008 May 1604 1612
30. E. Gane, C. Stedman, and R. Hyland ELECTRON: once daily PSI-7977 plus RBV in HCV GT1/2/3 J Hepatol 56 Suppl. 2 2012 S438 S439
31. E. Lawitz, J.P. Lalezari, and T. Hassanein PROTON: PSI-7977 & Peg/RBV in treatment-naïve patients with HCV GT1: sustained virologic response Hepatology 54 Suppl. 1 2011 472A
32. K. Kowdley, E. Lawitz, and I. Crespo Atomic: 97% RVR for PSI-7977 plus PEG/RBV × 12 week regimen in HCV GT1: an end to response guided therapy? J Hepatol 56 Suppl. 2 2012 S1
33. P. Pockros, D. Jensen, and N. Tsai First SVR data with the nucleoside analogue polymerase inhibitor mericitabine [RG7128] combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial J Hepatol 54 Suppl. 1 2011 S538
34. P. Pockros, D. Jensen, and N. Tsai SVR12 among G1/4 treatment-naïve patients receiving mericitabine in combination with PEG-IFNα-2A/RBV: Interim analysis from the JUMP-C study J Hepatol 56 Suppl. 2 2012 S477 S478
35. S. Le Pogam, A. Seshaadri, and A. Kosaka Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients J Antimicrob Chemother 61 6 2008 Jun 1205 1216
36. S. Zeuzem, T. Asselah, and P.W. Angus High sustained virologic response following interferon-free treatment of chronic HCV GT1 infection for 4 weeks with HCV protease inhibitor BI201335, polymerase inhibitor BI207127 and ribavirin, followed by BI201335 and pegIFN/ribavirin - the SOUND-C1 study Hepatology 54 Suppl. 1 2011 486A
37. D. Nelson, E.J. Gane, and I.M. Jacobson VX-222/Telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naïve genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interim analysis Hepatology 54 Suppl. 1 2011 1435A
38. G. Foster, P. Buggisch, and P. Marcellin Four-week treatment with GS-9256 and tegobuvir [GS-9190], ± RBV ± PEG, results in enhanced viral suppression on follow-up PEG/RBV therapy, in genotype 1a/1b HCV patients J Hepatol 54 Suppl. 1 2011 S172
39. E. Lawitz, I. Jacobson, and E. Godofsky A phase 2b trial comparing 24 to 48 weeks treatment with tegobuvir [GS-9190]/PEG/RBV to 48 weeks treatment with PEG.RBV for chronic genotype 1 HCV infection J Hepatol 54 Suppl. 1 2011 S181
40. F. Poordad, E. Lawitz, and E. DeJesus ABT-072 or ABT-333 combined with pegylated interferon/ribavirin after 3-day monotherapy in HCV genotype 1 [GT1]-Infected treatment-naïve subjects: 12-week sustained virologic response [SVR12] and safety results J Hepatol 56 Suppl. 2 2012 S478
41. F. Poordad, E. Lawitz, and K.V. Kowdley 12-week interferon-free regimen of ABT-450/r + ABT-333 + ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders J Hepatol 56 Suppl. 1 2012 S549 S550
42. D. Moradpour, F. Penin, and C.M. Rice Replication of hepatitis C virus Nat Rev Microbiol 5 6 2007 Jun 453 463
43. T.L. Tellinghuisen, K.L. Foss, and J. Treadaway Regulation of hepatitis C virion production via phosphorylation of the NS5A protein PLoS Pathog 4 3 2008 Mar e1000032
44. T.L. Foster, P. Gallay, and N.J. Stonehouse Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner J Virol 85 14 2011 Jul 7460 7464
45. S. Kim, C. Welsch, and M. Yi Regulation of the production of infectious genotype 1a hepatitis C virus by NS5A domain III J Virol 85 13 2011 Jul 6645 6656
46. M. Gao, R.E. Nettles, and M. Belema Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 7294 2010 May 6 96 100
47. R.E. Nettles, M. Gao, and M. Bifano Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 Hepatology 54 6 2011 Dec 1956 1965
48. A. Lok, D. Gardiner, and C. Hezode Confirmation that quadruple therapy with daclatasvir [NS5A inhibitor], asunaprevir [NS3 inhibitor] and Peginterferon/Ribavirin results in a high rate of SVR4 in HCV genotype 1 null responders J Hepatol 56 Suppl. 2 2012 S557
49. A. Lok, D. Gardiner, and E. Lawitz Quadruple therapy with BMS-790052, BMS-650032 and peg-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders J Hepatol 54 Suppl. 1 2011 S536
50. C. Hezode, G.M. Hirschfield, and W. Ghesquiere BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV- genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results Hepatology 54 Suppl. 1 2011 474A
51. A. Kaul, S. Stauffer, and C. Berger Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics PLoS Pathog 5 8 2009 Aug e1000546
52. X. Hanoulle, A. Badillo, and J.M. Wieruszeski Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B J Biol Chem 284 20 2009 May 15 13589 13601
53. J. Paeshuyse, A. Kaul, and E. De Clercq The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro Hepatology 43 4 2006 Apr 761 770
54. R. Flisiak, S.V. Feinman, and M. Jablkowski The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients Hepatology 49 5 2009 May 1460 1468
55. J. Pawlotsky, S.K. Sarin, and G.R. Foster Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from VITAL-1 phase 2b study J Hepatol 56 Suppl. 2 2012 S553
56. C.L. Jopling, M. Yi, and A.M. Lancaster Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA Science 309 5740 2005 Sep 2 1577 1581
57. T. Shimakami, D. Yamane, and R.K. Jangra Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex Proc Natl Acad Sci U S A 109 3 Jan 17 2012 941 946
58. J.I. Henke, D. Goergen, and J. Zheng MicroRNA-122 stimulates translation of hepatitis C virus RNA EMBO J 27 24 2008 Dec 17 3300 3310
59. Y.P. Li, J.M. Gottwein, and T.K. Scheel MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR Proc Natl Acad Sci U S A 108 12 2011 Mar 22 4991 4996
60. H. Reesink, H.L.A. Janssen, and S. Zeuzem Final results - randomized, double-blind, placebo-controlled safety, anti-viral proof-of-concept study of miravirsen, an oligonucleotide targeting miR-122, in treatment-naive patients with genotype 1 chronic HCV infection J Hepatol 56 Suppl. 2 2012 S26
61. S. Zeuzem, V. Soriano, and T. Asselah Virologic response to an interferon-free regimen of BI201335 and BI207127, with and without ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: week 12 interim results of the SOUND-C2 study Hepatology 54 Suppl. 1 2011 1436A
62. E. Gane, P. Pockros, and S. Zeuzem Interferon free treatment with a combination of mericitabine and danoprevir with or without ribavirin in treatment-naïve HCV genotype 1 infected patients J Hepatol 56 Suppl. 2 2012 S555 S556
63. M. Sulkowski, D. Gardiner, and E. Lawitz Potent viral suppression with the all-oral combination of daclatasvir [NS5A inhibitor] and GS-7977 [nucleotide NS5B inhibitor], +/- ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3 J Hepatol 56 Suppl. 1 2012 S560
64. E. Lawitz, F. Poordad, and K.V. Kowdley A 12-week interferon-free regimen of ABT-450r, ABT-072 and ribavirin was well tolerated and achieved sustained virological response in 91% of treatment-naive HCV IL28B-CC genotype-1 infected patients J Hepatol 56 Suppl. 1 2012 S7
65. F. Suzuki, K. Ikeda, and J. Toyota Dual oral therapy with NS5A inhibitor daclatasvir [BMS-790052] and NS3 protease inhibitor asunaprevir [BMS-650032] in HCV genotype 1b-Infected null responders or patients ineligible/intolerant to peginterferon/ribavirin J Hepatol 56 Suppl. 1 2012 S7 S8
66. B. Kupfer HCV structure and viral replication 2012 Flying Publisher
67. http://clinicaltrials.gov/ct2/show/NCT01343888?term=bi201335&rank=4
68. http://clinicaltrials.gov/ct2/show/NCT01353911?term=mk-5172&rank=4
69. J. Lalezari, W. O'Riordan, and F. Poordad The IDX-08C-004 investigator group a phase IIa study of IDX184 in combination with pegylated interferon (pegIFN) and ribavirin (RBV) in treatment-naïve genotype 1 HCV-infected subjects October 29-November 2, 2010 AASLD 2010 Boston
70. F. Wagner, R. Thompson, and C. Kantaridis Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients Hepatology 54 2011 50 59
71. http://clinicaltrials.gov/ct2/show/NCT00987337?term=filibuvir&rank=1
72. http://clinicaltrials.gov/ct2/show/NCT01466790?term=psi-7977&rank=7
73. http://clinicaltrials.gov/ct2/show/NCT01497366?term=psi-7977&rank=8
74. http://clinicaltrials.gov/ct2/show/NCT01359644?term=psi-7977&rank=9
75. http://clinicaltrials.gov/ct2/show/NCT01516918?term=vx-222&rank=1
76. http://clinicaltrials.gov/ct2/show/NCT01464827?term=abt-450&rank=5
77. http://clinicaltrials.gov/ct2/show/NCT01435226?term=tegobuvir&rank=1
78. http://clinicaltrials.gov/ct2/show/NCT01455090?term=bms791325&rank=1
79. http://clinicaltrials.gov/ct2/show/NCT01483742?term=danoprevir&rank= 15
80. http://clinicaltrials.gov/ct2/show/NCT01482390?term=mericitabine& rank=1
81. http://clinicaltrials.gov/ct2/show/NCT01482403?term=mericitabine& rank=2
82. http://clinicaltrials.gov/ct2/show/NCT01072695?term=gs9256&rank=2